A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

The researchers wrote that their findings showcase the need for close monitoring of patients and for effective treatments for those with recurrent infection, which occurs in 15%-30% of all patients ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

NICE commissioned an external assessment centre (EAC) to review the evidence. This section summarises that review. Full details of all the evidence are in the project documents on the NICE website.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Two ...

Please provide your email address to receive an email when new articles are posted on . Rebyota was effective in real-world analyses, with results consistent with the PUNCH CD3 trial. Rebyota was also ...

AstraZeneca (AZN) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Jessica R. Allegretti, MD, MPH, spoke with Healio about ...

The external assessment centre (EAC) did not identify any in-scope RCTs comparing FMT with antibiotics for refractory C. difficile infections. The clinical experts said that there is no consensus on ...